Global disparities and future directions in cardio-oncology training: an international survey of cardiology trainees from the international cardio-oncology society
Cardio-oncology has emerged as a vital subspecialty as the population of cancer patients with cardiovascular comorbidities and treatment-related cardiotoxicities grows. Despite its clinical importance, concerns have been raised as to the integration of cardio-oncology into cardiology training. To understand the global landscape of cardio-oncology training, the International Cardio-Oncology Society (IC-OS) carried out a survey of cardio-oncology education. An electronic survey of international cardiology trainees was conducted between March and July 2024. The survey assessed the extent of cardio-oncology teaching, clinical exposure, awareness of cardio-oncology guidelines and professional societies, and interest in future fellowship, research and career in cardio-oncology. 131 cardiology trainees from across the globe responded to the survey, (51% early years trainees, 49% late years trainees). 65% of respondents had cardio-oncology services at their current place of work. Only 39% of respondents reported receiving specific training in cardio-oncology, with significantly global disparity (UK, USA and Canada trainees = 64%, rest of the world 37%, p < 0.001). Clinical exposure was limited, with only 20% of trainees reporting having carried out inpatient cardio-oncology consultations and 17% reporting no cardio-oncology experience. Awareness of the cardio-oncology guidelines was good (75%), with awareness associated confidence in practicing cardio-oncology, as were receiving cardio-oncology training and > 50 h of clinical cardio-oncology experience. This study highlights the urgent need for global standardization of cardio-oncology training, expanded fellowship programs, and increased awareness of guidelines and societies. Addressing these gaps is essential to ensure equitable, high-quality cardiovascular care for cancer patients worldwide.
Authors
- Arjun Ghosh (ORCID: https://orcid.org/0009-0009-7929-7487)
- Daniel J. Lenihan (ORCID: https://orcid.org/0000-0001-9458-0154)
- James M. Wilson (ORCID: https://orcid.org/0000-0002-9630-3131)
- S. Dent
- Carolina Carvalho Silva
- Rhys Gray (ORCID: https://orcid.org/0000-0003-2720-6933)
- J Lushington
- Daniel Sierra-Lara Martinez
- José Álvarez
- Sebastian Szmit
- Stephen Caselli
- Cristian Herrera Flores
Institutions
- University College Hospital (GB)
- St Bartholomew's Hospital (GB)
- Queen Mary University of London (GB)
- City University of New York (US)
- Tecnológico Nacional de México (MX)
- D’Or Institute for Research and Education (BR)
- Saint Francis Medical Center (US)
- National Institute of Oncology (HU)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Postgraduate School of Molecular Medicine (PL)
- Vietnam National Children's Hospital (VN)
- William Harvey Research Institute (GB)
- University College London (GB)
- University of Rochester (US)
- New York University (US)
Publication Details
- Journal
- Cardio-Oncology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1186/s40959-025-00419-1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00